Aardvark Therapeutics (AARD) Assets Average (2025 - 2026)
Aardvark Therapeutics (AARD) reported Assets Average of $107.9 million for Q1 2026, down 8.0% on a YoY basis from $117.3 million in Q1 2025, and down 13.83% sequentially from $125.2 million in Q4 2025.
Aardvark Therapeutics (AARD) Assets Average (2025 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 2 years of Assets Average data on file, last reported at $107.9 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 8.0% year-over-year to $107.9 million; the trailing twelve-month figure through Mar 2026 stood at $107.9 million (down 8.0% YoY), and the FY2025 full-year result was $97.3 million, changed N/A from the prior year.
- Assets Average declined to $107.9 million in Q1 2026, from $125.2 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $152.2 million in Q2 2025 to a low of $107.9 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 65.01 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 40.89 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 8.37 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.30 Bn |
| 10 | Aardvark Therapeutics | 143.99 Mn | 24.02 Mn | - | 107.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 107.89 Mn |
| Dec 31, 2025 | 125.21 Mn |
| Sep 30, 2025 | 140.35 Mn |
| Jun 30, 2025 | 152.25 Mn |
| Mar 31, 2025 | 117.27 Mn |